Talphera announced reaching 50% patient enrollment in its NEPHRO CRRT clinical study with all 12 sites active, supporting expected study completion in 2026. The company closed a $4.1 million financing tranche linked to this milestone and reported $20.4 million in cash and investments as of December 31, 2025. Operating expenses rose due to ongoing development and trial costs, with 2026 expenses forecasted at $17-18 million to finalize the study and prepare for FDA submission. Talphera also hosted a virtual investor day featuring principal investigators discussing the potential of nafamostat to address unmet needs in anticoagulation during CRRT.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
